Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G-R Burmester

Showing results (371-380 of 380) with videos related to

Pageof 38
Sort By:
You have reached the last page of results.This site can display upto 380 results.
Clinical and Experimental Rheumatology|September 13, 2011
The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximabF Heldmann, J Brandt, I E van der Horst-Bruinsma, et al.
Arthritis and Rheumatism|May 4, 2011
Toward a data-driven evaluation of the 2010 American College of Rheumatology/European League Against Rheumatism criteria for rheumatoid arthritis: is it sensible to look at levels of rheumatoid factor?M P M van der Linden, M R Batstra, L E Bakker-Jonges, et al.
Annals of the Rheumatic Diseases|March 31, 2012
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011D E Furst, E C Keystone, J Braun, et al.
Annals of the Rheumatic Diseases|February 23, 2011
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010D E Furst, E C Keystone, J Braun, et al.
Annals of the Rheumatic Diseases|October 29, 2000
Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000)D E Furst, F C Breedveld, G R Burmester, et al.
Zeitschrift Fur Rheumatologie|June 8, 2017
[Safety and efficacy of off-label use of biologic therapies in patients with inflammatory rheumatic diseases refractory to standard of care therapy : Data from a nationwide German registry (GRAID2)]F Proft, H Schulze-Koops, M Grunke, et al.
Annals of the Rheumatic Diseases|December 17, 2008
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008D E Furst, E C Keystone, B Kirkham, et al.
Lupus|November 11, 2011
Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus reportM Aringer, H Burkhardt, G R Burmester, et al.
Annals of the Rheumatic Diseases|December 10, 2009
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009D E Furst, E C Keystone, R Fleischmann, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 29, 2009
European S3-guidelines on the systemic treatment of psoriasis vulgarisD Pathirana, A D Ormerod, P Saiag, et al.
Pageof 38

Showing results (371-380 of 380) with videos related to

Sort By:
Pageof 38
You have reached the last page of results.This site can display upto 380 results.
Clinical and Experimental Rheumatology|September 13, 2011
The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximabF Heldmann, J Brandt, I E van der Horst-Bruinsma, et al.
Arthritis and Rheumatism|May 4, 2011
Toward a data-driven evaluation of the 2010 American College of Rheumatology/European League Against Rheumatism criteria for rheumatoid arthritis: is it sensible to look at levels of rheumatoid factor?M P M van der Linden, M R Batstra, L E Bakker-Jonges, et al.
Annals of the Rheumatic Diseases|March 31, 2012
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011D E Furst, E C Keystone, J Braun, et al.
Annals of the Rheumatic Diseases|February 23, 2011
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010D E Furst, E C Keystone, J Braun, et al.
Annals of the Rheumatic Diseases|October 29, 2000
Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000)D E Furst, F C Breedveld, G R Burmester, et al.
Zeitschrift Fur Rheumatologie|June 8, 2017
[Safety and efficacy of off-label use of biologic therapies in patients with inflammatory rheumatic diseases refractory to standard of care therapy : Data from a nationwide German registry (GRAID2)]F Proft, H Schulze-Koops, M Grunke, et al.
Annals of the Rheumatic Diseases|December 17, 2008
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008D E Furst, E C Keystone, B Kirkham, et al.
Lupus|November 11, 2011
Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus reportM Aringer, H Burkhardt, G R Burmester, et al.
Annals of the Rheumatic Diseases|December 10, 2009
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009D E Furst, E C Keystone, R Fleischmann, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 29, 2009
European S3-guidelines on the systemic treatment of psoriasis vulgarisD Pathirana, A D Ormerod, P Saiag, et al.
Pageof 38